Báo cáo y học: " Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study | Paparrigopoulos et al. BMC Psychiatry 2011 11 41 http 1471-244X 11 41 BMC Psychiatry RESEARCH ARTICLE Open Access Treatment of alcohol dependence with low-dose topiramate an open-label controlled study 1 1 1 2 1 Thomas Paparrigopoulos Elias Tzavellas Dimitris Karaiskos Georgia Kourlaba loannis Liappas 1 Abstract Background GABAergic anticonvulsants have been recommended for the treatment of alcohol dependence and the prevention of relapse. Several studies have demonstrated topiramate s efficacy in improving drinking behaviour and maintaining abstinence. The objective of the present open-label controlled study was to assess efficacy and tolerability of low-dose topiramate as adjunctive treatment in alcohol dependence during the immediate postdetoxification period and during a 16-week follow-up period after alcohol withdrawal. Methods Following a 7-10 day inpatient alcohol detoxification protocol 90 patients were assigned to receive either topiramate up to 75 mg per day in addition to psychotherapeutic treatment n 30 or psychotherapy alone n 60 . Symptoms of depression and anxiety as well as craving were monitored for 4-6 weeks immediately following detoxification on an inpatient basis. Thereafter both groups were followed as outpatients at a weekly basis for another 4 months in order to monitor their course and abstinence from alcohol. Results A marked improvement in depressive p anxiety p and obsessive-compulsive drinking symptoms p was observed over the consecutive assessments in both study groups. However individuals on topiramate fared better than controls p during inpatient treatment. Moreover during the 4-month follow up period relapse rate was lower among patients who received topiramate compared to those who received no adjunctive treatment p . Time to relapse in the topiramate augmentation group was significantly longer compared to the control group log rank test p . Thus median duration of .

Không thể tạo bản xem trước, hãy bấm tải xuống
232    3    1    25-05-2024
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.